SHILPA MEDICARE LTD. - Shilpa Medicare Limited (SML) Receives Noc From RCGM, Dept. Of Biotechnology For Its Biosimilar Aflibercept - Intimation U/R 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015
Download 
|
< Back |
| 25 Apr 2022 | |
| This is to inform you that the Company, via its wholly owned subsidiary, Shilpa Biologicals Private Limited (SBPL), has received a NoC from RCGM, Dept of Biotechnology to approach the DCGI to conduct Clinical studies for its Biosimilar Aflibercept - a first from an Indian company. The product is a biosimilar version of EYLEA?? of Regeneron for which currently there is no other biosimilar version on the Indian market. | |
| View all announcements for SHILPA MEDICARE LTD. | Source: BSE India |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback